Article Menu

Export Article

More by Authors Links

Article Data

  • Views 2079
  • Dowloads 154

Reviews

Open Access

An elderly patient with primary cervical CD5-positive diffuse large B-cell lymphoma: a case report and review of the literature

  • Gengrong Liu1
  • Zhenglei Shen1
  • Liefen Yin1,*,
  • Zhe Zhang2
  • Lingmei Yin2
  • Ke Wang2
  • Huan Yang2
  • Jin Yao2

1Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, P. R. China

2Department of Hematology, Yunnan Tumor Hospital, Kunming, Yunnan, P. R. China

DOI: 10.31083/j.ejgo.2020.04.5298 Vol.41,Issue 4,August 2020 pp.500-503

Submitted: 18 June 2019 Accepted: 08 August 2019

Published: 15 August 2020

*Corresponding Author(s): Liefen Yin E-mail: ylfynkm@126.com

PDF (412.41 kB) View Full-text

Abstract

Objective: To increase our understanding of the clinical features, diagnosis and treatment, and prognosis of primary cervical CD5+ diffuse large B-cell lymphoma (DLBCL) in an elderly patient. Materials and Methods: We analyzed a case of an elderly patient with primary cervical CD5+ DLBCL and reviewed the literature. Results: The clinical features of this patient were not specific and were manifested as fever, significantly elevated LDH, normal blood test results, an unidentified fraction (6.5%) of cells shown by bone marrow puncture, unexpressed T-system and medullary system markers, and a primary lesion of the cervix found upon positron emission tomography-computed tomography (PET-CT). Cervical biopsy plus immunohistochemical staining showed a CD5+DLBCL, and the diagnosis was confirmed and R-CHOP therapy achieved a favorable therapeutic effect. Conclusions: The clinical manifestations of primary cervical CD5+DLBCL are not specific but PET-CT combined with cervical biopsy can clarify the diagnosis with R-CHOPas the preferred therapeutic regimen.

Keywords

Elderly; Cervical; Diffuse large B cell lymphoma; CD5

Cite and Share

Gengrong Liu,Zhenglei Shen,Liefen Yin,Zhe Zhang,Lingmei Yin,Ke Wang,Huan Yang,Jin Yao. An elderly patient with primary cervical CD5-positive diffuse large B-cell lymphoma: a case report and review of the literature. European Journal of Gynaecological Oncology. 2020. 41(4);500-503.

URL:

https://www.ejgo.net/articles/10.31083/j.ejgo.2020.04.5298

References

[1] Calli A.O., Rezanko T., Yigit S., Payzin B.: “Lymphoma of the cervix: A diagnostic pitfall on cervicovaginal smear”. J. Cytol., 2012. 29, 213.

[2] Thakral B., Medeiros L.J., Desai P., Lin P., Yin C.C., Tang G., et al.: “Prognostic impact of CD5 expression in diffuse large B­cell lym­ phoma in patients treated with rituximab­EPOCH”. Eur. J. Haema­ tol., 2017, 98, 415.

[3] Semczuk A., Skomra D., Korobowicz E., Balon B., Rechberger T.: “Primary non­Hodgkin’s lymphoma of the uterine cervix mimicking leiomyoma: case report and review of the literature”. Pathol. Res. Pract., 2006, 202, 61.

[4] Korcum A.F., Karadogan I., Aksu G., Aralasmak A., Erdogan G.: “Primary follicular lymphoma of the cervix uteri: a review”. Ann. Hematol., 2007, 86, 623.

[5] Kosari F., Daneshbod Y., Parwaresch R., Krams M., Wacker H.H.: “Lymphomas of the female genital tract: a study of 186 cases and review of the literature”. Am. J. Surg. Pathol., 2005, 29, 1512.

[6] Cubo A.M., Soto Z.M., Cruz M.Á., Doyague M.J., Sancho V., Fraino A., et al.: “Primary diffuse large B cell lymphoma of the uter­ine cervix successfully treated by combined chemotherapy alone: A case report”. Medicine (Baltimore), 2017, 96, e6846.

[7] Pósfai É., Nagy K., Marton I., Bánfalvi A., Kocsis L., Cserni G.: “Incidentally discovered diffuse large B­-cell lymphoma limited to the endocervical mucosa in a young female patient”. Gynecol. Ob­stet. Invest., 2015, 80, 134.

[8] Mandato V.D., Palermo R., Falbo A., Capodanno I., Capodanno F., Gelli M.C., et al.: “Primary diffuse large B­-cell lymphoma of the uterus: case report and review”. Anticancer Res., 2014, 34, 4377.

[9] Kano R., Masaie H., Hino A., Yasuoka H., Nagata S., Ishikawa J., et al.: “Pure intravascular recurrence of CD5­positive diffuse large B-­cell lymphoma primarily arising from the nasal cavities”. Diagn. Pathol., 2018, 13, 46.

[10] Jain P., Fayad L.E., Rosenwald A., Young K.H., O’Brien S.: “Re­cent advances in de novo CD5+ diffuse large B cell lymphoma”. Am. J. Hematol., 2013, 88, 798.

[11] Alinari L., Gru A., Quinion C., Huang Y., Lozanski A., Lozanski G., et al.: “De novo CD5+ diffuse large B­cell lymphoma: Adverse out­comes with and without stem cell transplantation in a large, multi­center, rituximab treated cohort”. Am. J. Hematol., 2016, 91, 395.

[12] Niitsu N., Okamoto M., Tamaru J.I., Yoshino T., Nakamura S., Ohshima K., et al.: “Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5­ positive in comparison with CD5­negative diffuse large B­cell lym­phoma”. Ann. Oncol., 2010, 21, 2069.

[13] Hyo R., Tomita N., Takeuchi K., Aoshima T., Fujita A., Kuwabara H., et al.: “The therapeutic effect of rituximab on CD5­positive and CD5­negative diffuse large B­cell lymphoma”. Hematol. On­col., 2010, 28, 27.

[14] Zhou W., Hua F., Zuo C., Guan Y.: “Primary Uterine Cervical Lym­phoma Manifesting as Menolipsis Staged and Followed Up by FDG PET/CT”. Clin. Nucl. Med., 2016, 41, 590.

[15] Huang H., Li Z., Huang C., Rao J., Xie Q., Cui W., et al.: “CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients”. Open Med. (Wars.), 2018, 13, 605.

Submission Turnaround Time

Top